215 filings
6-K
THTX
Theratechnologies Inc.
15 Apr 24
Notice of Annual Meeting of Shareholders
9:31am
6-K
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
6-K
THTX
Theratechnologies Inc.
10 Apr 24
Theratechnologies Reports Financial Results
8:16am
6-K
THTX
Theratechnologies Inc.
5 Apr 24
Theratechnologies Appoints Elina Tea to its Board of Directors
12:57pm
6-K
THTX
Theratechnologies Inc.
22 Mar 24
Theratechnologies Announces Update on its Preclinical Oncology Research Program
4:27pm
6-K
28sc4qw2m6xvjie
22 Mar 24
Theratechnologies Appoints Jordan Zwick to its Board of Directors
1:37pm
6-K
2g4580y
21 Mar 24
Current report (foreign)
12:40pm
6-K
i3dqygs91 2ec
29 Feb 24
Theratechnologies Announces the Resignation of One of Its
4:55pm
6-K
lbrbax5 1zt
27 Feb 24
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular
8:37am
6-K
h5u 8sl6smr3
21 Feb 24
Theratechnologies Reports Financial Results
8:00am
6-K
642zeob85udztig8t
15 Feb 24
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
8:36am
SC 13G
qloyhvp4
14 Feb 24
Theratechnologies / Nantahala Capital Management ownership change
4:51pm
SC 13G/A
lxznm2q
7 Feb 24
Theratechnologies / HIRSCHMAN ORIN ownership change
6:55pm
6-K
96b7y6h
6 Feb 24
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial
2:29pm
6-K
wv30w
1 Feb 24
Material Change Report
11:50am
6-K
ha4h iyulwas6d
24 Jan 24
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
1:52pm
6-K
nq2k2obqc3gawcug
23 Jan 24
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental
2:01pm
EFFECT
1pam1s0mk9rphpvn
4 Jan 24
Notice of effectiveness
12:15am
F-3/A
yt4 xugks5zbt9
2 Jan 24
Shelf registration (foreign) (amended)
4:28pm